Margaret R. Warner

Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial

Kenneth G. Saag, José Zanchetta, Jean‐Pierre Devogelaer et al. · Arthritis & Rheumatism · 2009 · 495 citations

Medicine, Pharmacology, Pharmacotherapy +17

INTERACTION BETWEEN THE PHOSPHODIESTERASE 5 INHIBITOR, TADALAFIL AND 2 α-BLOCKERS, DOXAZOSIN AND TAMSULOSIN IN HEALTHY NORMOTENSIVE MEN

Robert A. Kloner, Graham Jackson, Jeffrey T. Emmick et al. · The Journal of Urology · 2004 · 154 citations

Medicine, Pharmacology, Pharmacotherapy +16

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases

Akimitsu Miyauchi, Toshio Matsumoto, Toshitsugu Sugimoto et al. · Bone · 2010 · 147 citations

Medicine, Orthopedic Surgery, Pharmacotherapy +16

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

Bente Langdahl, Fernando Marín, Elizabeth Shane et al. · Osteoporosis International · 2009 · 125 citations

Medicine, Endocrinology, Pharmacotherapy +16

An open‐label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy

Ian Eardley, Vincenzo Mirone, Francesco Montorsi et al. · British Journal of Urology · 2005 · 95 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11